IPG Photonics (IPGP) Proxy filing summary

Executive summary

• Achieved a return to growth in 2025 with a 3% sales increase, first since 2021, driven by expansion in medical, micromachining, and advanced applications.

• Q1 2026 revenue rose 17% year-over-year, reflecting continued momentum.

• Stock price increased over 37% since June 2024, outperforming the Russell 3000.

• Operating model shifted to a more disciplined, team-led structure to enhance accountability and predictability.

• Strong balance sheet at end of 2025 with $839M in cash and short-term investments, zero debt, and $50M in share buybacks.

Voting matters and shareholder proposals

• Board recommends voting for all three management proposals: election of ten directors, advisory approval of executive compensation, and ratification of Deloitte & Touche LLP as auditor for 2026.

Board of directors and corporate governance

• Dr. Gitin appointed CEO in June 2024, marking the first external CEO hire since founding.

• Board has overseen strategic transformation and supports ongoing leadership changes.